/ Print /

IN THE PIPELINE

New hypersonic vitrector introduces concept of ‘vitreous liquefaction’
New hypersonic vitrector introduces concept of ‘vitreous liquefaction’A new hypersonic liquefaction vitrectomy system, called Vitesse PPVX (Bausch + Lomb), offers several advantages over currently available vitrector technology. The device received FDA 510k approval in April 2017.
How adaptive optics will change retinal imaging
How adaptive optics will change retinal imagingAdaptive optics could allow clinicians to monitor the progression of retinal diseases cell-by-cell, according to Jacque Duncan, MD.
Systemic safety of anti-VEGF treatment for ROP mandates further study
Systemic safety of anti-VEGF treatment for ROP mandates further studyAccumulating evidence is cause for concern and underscoring the need for more research evaluating the safety of anti-VEGF injections for ROP, according to Robert L. Avery, MD.
FDA approves EpiPen rivalAdamis’ epinephrine injection promises to be a lower-cost alterative to EpiPen.
First patients enrolled in dry eye device studyPatient recruitment has started in a randomised clinical trial testing an experimental device (Lamelleye, known also as CXB/1-14) for the treatment of dry eye disease (DED).
Ebola may leave retinal scarThe Ebola virus may leave a retinal scar specific to the disease, according to researchers. “The distribution of these retinal scars or lesions provides the first observational evidence that the virus enters the eye via the optic nerve to reach the retina in a similar way to West Nile virus,” said Dr Paul Steptoe of the Royal Liverpool Hospital, in a press release.
Glaucoma monitoring implant receives CE markAn implantable glaucoma sensor has received CE mark approval for marketing in the European Union. The sensor (Eyemate, Implandata Ophthalmic Products) can provide frequent IOP readings, informing patients and their physicians about how the pressure changes by time of day and from one day to another.
FDA approves first generic Truvada for HIVThe first generic Truvada for treating and preventing HIV will be available, but when?
FDA gives once-daily HIV therapy go-aheadFDA approves Isentress at a higher dose for HIV-1 infected patients.
Asthma biologic may reduce oral steroid useA new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.